reports
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
NEOG NEOGEN CORPORATION
LAKE LAKELAND INDUSTRIES INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
ALOT ASTRONOVA INC.
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
PASG PASSAGE BIO
RLAY INC.
CTGO RELAY THERAPEUTICS
TEAF CONTANGO ORE INC.
PROK ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
MIO PROKIDNEY CORP.
DMA PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
ADVM DESTRA MULTI ALTERNATIVE FUND
GF ADVERUM BIOTECHNOLOGIES INC.
THE NEW GERMANY FUND
INC.
RGC Resources, Inc. Schedules Second Quarter 2025 Earnings Call
RGC Resources, Inc. Schedules Second Quarter 2025 Earnings Call ROANOKE, Va., April 24, 2025 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (NASDAQ: RGCO) will host its quarterly conference call and webcast to review the results of its fiscal second quarter 2025 on Thursday, May 8, 2025 at 9:00 a.m. eastern time. Related presentation materials will be available before the call on the Company website on the Investor & Financial Information page at . Interested parties may access the conference call by dialing toll-free 1-877-304-9269 and entering conference identification number 917621. An archi...
Pacira BioSciences to Present 104-Week Efficacy Data Following a Singl...
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee -- Poster to be presented at OARSI World Congress on Osteoarthritis -- BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the upcoming presentation of new 104-week data in support of its locally administered gene therapy candidate, PCRX-201 (eneki...
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Sha...
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders -- $300 million aggregate share repurchase authorization-- -- Reinforces confidence in 5x30 plan – -- Continued focus on margin expansion and operational efficiency -- BRISBANE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reaffirmed its commitment to enhancing shareholder value by outlining a series of strategic actions designed ...
Northern Technologies International Corporation Announces Quarterly C...
Northern Technologies International Corporation Announces Quarterly Cash Dividend MINNEAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- Northern Technologies International Corporation (NASDAQ: NTIC), a leading developer of corrosion inhibiting products and services, as well as bio-based and biodegradable polymer resin compounds, today announced that the Board of Directors declared a quarterly cash dividend of $0.01 per share payable on May 14, 2025, to shareholders of record at the close of business on April 30, 2025. About Northern Technologies International Corporation Northern Techno...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People...
Northern Technologies International Corporation Reports Financial Resu...
Northern Technologies International Corporation Reports Financial Results for Second Quarter Fiscal 2025 MINNEAPOLIS, April 10, 2025 (GLOBE NEWSWIRE) -- Northern Technologies International Corporation (NASDAQ: NTIC), a leading developer of corrosion inhibiting products and services, as well as bio-based and biodegradable polymer resin compounds, today reported its financial results for the second quarter of fiscal 2025. Second quarter fiscal 2025 financial and operating highlights include (with growth rates on a fiscal quarter year-over-year basis): Consolidated net sales decreased 8.5%...
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for ...
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL -- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 -- -- Fresenius also licensed to sell generic bupivacaine liposome injectable suspension in the U.S. without volume limitations beginning in 2039 -- BRISBANE, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the ...
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Eval...
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee -- Novel, locally administered gene therapy designed to boost cellular production of anti-inflammatory protein IL-1Ra in the knee -- -- Initial topline results from two-part, randomized, double-blind, active-controlled study expected late 2026 -- BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies ...
Northern Technologies International Corporation to Announce Fiscal 202...
Northern Technologies International Corporation to Announce Fiscal 2025 Second-Quarter Financial Results and Host Conference Call MINNEAPOLIS, April 03, 2025 (GLOBE NEWSWIRE) -- Northern Technologies International Corporation (NASDAQ: NTIC) today announced that it expects to release its fiscal 2025 second-quarter financial results on Thursday, April 10, 2025, before the market opens. A copy of the news release will be available on the Investor Relations section of NTIC’s webpage (). In conjunction with NTIC’s release of its financial and operating results, investors, analysts, and other ...
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizon...
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. About Sensei Biot...
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual ...
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:45 AM ET on Monday, April 7, 2025. Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s web...
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRGS PROGRESS SOFTWARE CORPORATION
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
MNRO MONRO INC
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
SAFE SAFEHOLD INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
- Jay Kornreich
- Richard Anderson
RGC Resources, Inc. Declares Quarterly Dividend
RGC Resources, Inc. Declares Quarterly Dividend ROANOKE, Va., March 28, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (NASDAQ: RGCO) declared a quarterly dividend of $0.2075 per share on the Company’s common stock. The dividend will be paid on May 1, 2025 to shareholders of record on April 17, 2025. This is the Company’s 324th consecutive quarterly cash dividend. RGC Resources, Inc. provides energy and related products and services to customers in Virginia through its operating subsidiaries including Roanoke Gas Company and RGC Midstream, L.L.C. The st...
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Up...
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: S...
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Da...
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors – Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial responses (PR), including one in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient, all of whom were previously treated with and progressed on immunother...
CPS Announces $65.0 Million Securitization of Residual Interests
CPS Announces $65.0 Million Securitization of Residual Interests LAS VEGAS, Nevada, March 20, 2025 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced the closing of a $65.0 million securitization of residual interests from previously issued securitizations. In the transaction, a qualified institutional buyer purchased $65.0 million of asset-backed notes secured by an 80% interest in a CPS majority owned affiliate (“MOA”) that owns the residual interests in five CPS securitizations issued from October 2023 through September 2024. ...
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA ...
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual -- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders. Pacira issued the follow...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PARSIPPANY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on March 4, 2025 to six new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.